Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

Clinical complete response of 43% seen for those with muscle-invasive bladder cancer receiving neoadjuvant gemcitabine, cisplatin, plus nivolumab

Related Keywords

New York ,United States ,Matthewd Galsky , ,Icahn School Of Medicine At Mount Sinai ,Healthday News ,Icahn School ,Mount Sinai ,New York City ,